MedTrace Logo

Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts

NCT04814446 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2025-01-23

No results posted yet for this study

Summary

Cutaneous viral warts are very common and are caused by the human papilloma virus (HPV). Most people experience warts in one form or another at some point in their lives. Cutaneous warts are related to different types of HPV. For the palms and soles, HPV 2 has been the most frequently found but HPV 1, 4, 27, and 57 have also been described. Our hypothesis is that vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts patients of more than 15 years and 3 months of age.

Conditions

  • Palmar or Plantar Warts

Interventions

BIOLOGICAL

Vaccination

Intramuscular injections of 0,5 ml will be administered at M0, M2 and M6

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Johan CHANAL, Dr · Hospital Cochin

  • Olivier CHOSIDOW, Pr · Henri Mondor University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-29
Primary Completion
2025-06-29
Completion
2026-06-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04814446 on ClinicalTrials.gov